Stewart J Tepper1, Juanzhi Fang2, Pamela Vo3, Ying Shen4, Lujia Zhou4, Ahmad Abdrabboh5, Mrudula Glassberg5, Matias Ferraris3. 1. Geisel School of Medicine at Dartmouth, Hanover, NH, USA. 2. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. jenny.fang@novartis.com. 3. Novartis Pharma AG, CH-4002, Basel, Switzerland. 4. KMK Consulting Inc., Morristown, NJ, USA. 5. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Abstract
BACKGROUND: Migraine is one of the leading causes of disability worldwide. Erenumab is a fully human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. This study aimed to evaluate real-world evidence on the impact of erenumab on acute medication usage and health care resource utilization (HCRU) among migraine patients. METHODS: This retrospective effectiveness study utilized the US Optum's de-identified Clinformatics® Data Mart database to identify migraine patients initiating erenumab between May 1, 2018 and September 30, 2019. Patients had to be at least 18 years old, with a minimum of three doses for erenumab in the 6-month post-index period and continuous medical/pharmacy coverage in the 12-month pre- and 6-month post-index period. The date of the first claim for erenumab served as the index date. Use of acute medications overall and at different drug class level, and HCRU were compared during the 6-month pre- vs. post-index period. Impact of erenumab on a composite endpoint of three possible events: 1) outpatient visit with a diagnosis of migraine and an associated acute medication claim within 7 days of the visit, 2) hospital admission with a primary diagnosis for migraine, or 3) emergency room visit with a primary diagnosis for migraine (any events that occurred ≤3 days apart were counted only once) was also evaluated. RESULTS: The analysis included 3171 identified patients. At 6 months, following initiation of erenumab, acute medication use including the number of types of acute medication, number of claims of each medication and % of patients who received acute medication, and HCRU were significantly decreased. For the composite outcome, the mean number of events decreased from 1.03 to 0.77 (rate ratio: 0.75; 95% CI: 0.71 to 0.79; P < 0.0001). A decrease in the proportion of patients with any of the three events was also observed (52.7% vs. 39.5%, P < 0.0001). CONCLUSION: In this retrospective analysis, erenumab was associated with significantly reduced acute medication use and HCRU in a real-world setting, hence significantly reducing the burden of the disease. A composite endpoint could be used as a proxy to evaluate the burden of migraine attacks; however, further research is needed.
BACKGROUND:Migraine is one of the leading causes of disability worldwide. Erenumab is a fully human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. This study aimed to evaluate real-world evidence on the impact of erenumab on acute medication usage and health care resource utilization (HCRU) among migrainepatients. METHODS: This retrospective effectiveness study utilized the US Optum's de-identified Clinformatics® Data Mart database to identify migrainepatients initiating erenumab between May 1, 2018 and September 30, 2019. Patients had to be at least 18 years old, with a minimum of three doses for erenumab in the 6-month post-index period and continuous medical/pharmacy coverage in the 12-month pre- and 6-month post-index period. The date of the first claim for erenumab served as the index date. Use of acute medications overall and at different drug class level, and HCRU were compared during the 6-month pre- vs. post-index period. Impact of erenumab on a composite endpoint of three possible events: 1) outpatient visit with a diagnosis of migraine and an associated acute medication claim within 7 days of the visit, 2) hospital admission with a primary diagnosis for migraine, or 3) emergency room visit with a primary diagnosis for migraine (any events that occurred ≤3 days apart were counted only once) was also evaluated. RESULTS: The analysis included 3171 identified patients. At 6 months, following initiation of erenumab, acute medication use including the number of types of acute medication, number of claims of each medication and % of patients who received acute medication, and HCRU were significantly decreased. For the composite outcome, the mean number of events decreased from 1.03 to 0.77 (rate ratio: 0.75; 95% CI: 0.71 to 0.79; P < 0.0001). A decrease in the proportion of patients with any of the three events was also observed (52.7% vs. 39.5%, P < 0.0001). CONCLUSION: In this retrospective analysis, erenumab was associated with significantly reduced acute medication use and HCRU in a real-world setting, hence significantly reducing the burden of the disease. A composite endpoint could be used as a proxy to evaluate the burden of migraine attacks; however, further research is needed.
Entities:
Keywords:
Burden; Efficacy; Erenumab; Health care resource utilization; Migraine; Preventive therapies; Real-world evidence
Authors: Andrew M Blumenfeld; Lisa M Bloudek; Werner J Becker; Dawn C Buse; Sepideh F Varon; Gregory A Maglinte; Teresa K Wilcox; Ariane K Kawata; Richard B Lipton Journal: Headache Date: 2013-03-04 Impact factor: 5.887
Authors: Licheng Shi; Sonya G Lehto; Dawn X D Zhu; Hong Sun; Jianhua Zhang; Brian P Smith; David C Immke; Kenneth D Wild; Cen Xu Journal: J Pharmacol Exp Ther Date: 2015-11-11 Impact factor: 4.030
Authors: Stewart J Tepper; Hans-Christoph Diener; Messoud Ashina; Jan Lewis Brandes; Deborah I Friedman; Uwe Reuter; Sunfa Cheng; Jon Nilsen; Dean K Leonardi; Robert A Lenz; Daniel D Mikol Journal: Neurology Date: 2019-04-17 Impact factor: 9.910
Authors: Luigi Francesco Iannone; Davide Fattori; Silvia Benemei; Alberto Chiarugi; Pierangelo Geppetti; Francesco De Cesaris Journal: CNS Drugs Date: 2022-02-11 Impact factor: 5.749
Authors: Stewart J Tepper; Messoud Ashina; Uwe Reuter; Yngve Hallström; Gregor Broessner; Jo H Bonner; Hernan Picard; Sunfa Cheng; Denise E Chou; Feng Zhang; Jan Klatt; Daniel D Mikol Journal: J Headache Pain Date: 2021-07-23 Impact factor: 7.277